Kiniksa Pharmaceuticals 주식 (NASDAQ: KNSA)

에 대한 최신 뉴스 Kiniksa Pharmaceuticals (NASDAQ:KNSA) 주식

Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

PonyAIFremont,,Ca,,Usa,-,Feb,28,,2020:,Autonomous,Driving,Startup

Equities

Mid Cap

News

Movers

CGON

FTDR

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IRTC

KNSA

MTSR

PONY

PRDO

포니AI·힘스핸허스 등 지난주 급등한 중형주 11종목 (4월 28일~5월 2일) 오디티 테크, 멧세라, CG 온콜로지, 키닉사 파마슈티컬스, 킹소프트, 프론트도어, ATI, 퍼도세오, 아이리듬

포니AI·힘스앤허스 등 지난주 급등한 중형주 11종목 (4월 28일~5월 2일)

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals International PLC

Wells Fargo analyst Jonathan Reeder maintains Brookfield Renewable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEP#NYSE">BEP</a>) with a Overweight and lowers the price target from $29 to $27.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Brookfield Renewable, Lowers Price Target to $27

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the financial sector.
<h3 class="wp-block-heading">Horizon Technology Finance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRZN#NASDAQ">HRZN</a>)</h3>
<ul>
<li>Dividend Yield: 17.89%</li>
<li>Keefe, Bruyette &amp; Woods analyst Paul Johnson maintained an Underperform rating and cut the price target from $8 to $7.5 on April 8, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Compass Point analyst Casey Alexander upgraded the stock from Sell to Neutral with a price target of $8.25 on Dec. 17, 2024. This analyst has an accuracy rate of 68%.</li>
<li>Recent News: On April 29, Horizon Technology Finance reported first-quarter financial results and missed its net and total investment income estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest HRZN <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505"><img loading="lazy" decoding="async" width="916" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050809/image-35.png" alt="" class="wp-image-900873" style="width:606px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050809/image-35.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050809/image-35-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050809/image-35-768x709.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">Ellington Credit Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>)</h3>
<ul>
<li>Dividend Yield: 17.78%</li>
<li>UBS analyst Douglas Harter maintained a Neutral rating and cut the price target from $6.5 to $5.25 on April 17, 2025. This analyst has an accuracy rate of 68%.</li>
<li>JMP Securities analyst Mikhail Goberman reiterated a Market Perform rating on April 19, 2024. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On April 3, Ellington Credit Company's Board of Trustees declared a monthly common dividend of $0.08 per share.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest EARN <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505"><img loading="lazy" decoding="async" width="912" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050844/image-2-14.png" alt="" class="wp-image-900876" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050844/image-2-14.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050844/image-2-14-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050844/image-2-14-768x713.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">AGNC Investment Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>)</h3>
<ul>
<li>Dividend Yield: 16.38%</li>
<li>RBC Capital analyst Kenneth Lee maintained an Outperform rating and cut the price target from $11 to $10 on April 29, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Wells Fargo analyst Donald Fandetti maintained an Overweight rating and slashed the price target from $11 to $10 on April 22, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: On April 21, AGNC Investment posted upbeat quarterly earnings.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest AGNC <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505"><img loading="lazy" decoding="async" width="915" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050916/image-36.png" alt="" class="wp-image-900878" style="width:597px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050916/image-36.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050916/image-36-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050916/image-36-768x690.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Markets

Trading Ideas

AGNC

EARN

HRZN

Wall Street's Most Accurate Analysts Give Their Take On 3 Financial Stocks With Over 10% Dividend Yields

Valaris Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) ("Valaris" or the "Company") announced today that it has been awarded a five-well contract offshore West Africa for drillship VALARIS DS-15. The contract is expected to commence in the third quarter 2026. The total contract value, based on an estimated duration of 250 days, is approximately $135 million, including upfront payments for rig upgrades and mobilization. The total contract value does not include the provision of additional services. The contract includes priced options for up to five wells with an estimated total duration of 80 to 100 days.

Valaris Secures $135M, Five-Well Offshore West Africa Contract For Drillship VALARIS DS-15

Proposed Terms of Merger
By signing the Letter of Intent, this potential transaction marks a distinct shift in a positive direction for existing BioSig shareholders.
<ul>
<li>Immediately after the Merger, the current stockholders of Streamex will own approximately 19.9% of the outstanding Common Stock of the Company and a number of Series X Convertible Preferred Stock, par value $0.0001 per share ("Series X"), such that after taking into account the conversion of the Series X, the former stockholders of Streamex will own approximately 75% of the outstanding Common Stock of the Company, with the Company's current stakeholders owning the remaining equity of the Company.</li>
</ul>

BSGM

BioSig Enters LOI To Merge With Streamex Exchange Corp; Current Stockholders Of Streamex Will Own ~19.9% Of Outstanding Common Stock Of Co. And A Number Of Series X Convertible Preferred Stock

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Vikram Purohit upgraded the rating for Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) from Equal-Weight to Overweight and raised the price target from $180 to $250. Ascendis Pharma shares closed at $172.06 on Friday. <a href="https://www.benzinga.com/quote/ASND/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst Brian McNamara upgraded Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) from Hold to Buy and boosted the price target from $54 to $67. Worthington Enterprises shares closed at $51.99 on Friday. <a href="https://www.benzinga.com/quote/WOR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC analyst Stephen Bersey upgraded Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) from Reduce to Hold and raised the price target from $77 to $99. Twilio shares closed at $100.11 on Friday. <a href="https://www.benzinga.com/quote/TWLO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst John Ivankoe upgraded the rating for The Wendy&#8217;s Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) from Neutral to Overweight but lowered the price target from $17 to $15. Wendy&#8217;s shares closed at $12.55 on Friday. <a href="https://www.benzinga.com/quote/WEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Aaron Kessler upgraded Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) from Neutral to Buy and announced a $165 price target. Reddit shares closed at $113.83 on Friday. <a href="https://www.benzinga.com/quote/RDDT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TWLO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="567" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-1024x567.png" alt="" class="wp-image-901223" style="width:628px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-1024x567.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-768x426.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

Upgrades

ASND

RDDT

TWLO

This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Wells Fargo analyst Jonathan Reeder maintains Brookfield Renewable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEPC#NYSE">BEPC</a>) with a Overweight and lowers the price target from $33 to $32.

BEPC

Wells Fargo Maintains Overweight on Brookfield Renewable, Lowers Price Target to $32

The U.S. Food and Drug Administration (FDA) on Monday cleared Lantern Pharma Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) Investigational New Drug Application (IND) for a Phase 1b/2 trial for LP-184 in triple-negative <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">breast cancer (TNBC)</a>.
The dual approach in the clinical trial is designed to evaluate LP-184 in recurrent, advanced-stage TNBC patients through:
<ul>
<li>Monotherapy Arm: An open-label study involving approximately 30 patients with advanced-stage TNBC, focusing on dose optimization to evaluate, enhance, and optimize safety and potential efficacy for TNBC patients.</li>
<li>Combination Therapy: Evaluation of LP-184 in combination with olaparib in second-line settings for patients with advanced-stage TNBC harboring BRCA1 or BRCA2 alterations, with primary endpoints including safety and efficacy parameters that could support a pathway to regulatory approval.In preclinical studies, treating an animal model with BRCA-1 LOH and an HRD score of 63 resistant to the PARP inhibitor showed evidence of resensitization in combination with LP-184.</li>
<li>The combination phase 1b/2 trial design provides for LP-184 to be evaluated in a second-line setting in patients with advanced-stage TNBC whose primary tumor harbors alterations in BRCA1 or BRCA2.</li>
</ul>
In 2024, LP-184 received Fast Track Designations from the FDA for GBM (Glioblastoma Multiforme)&nbsp;and&nbsp;TNBC.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43741954/small-cap-os-therapies-inks-commercial-manufacture-agreements-for-its-lead-cancer-drug-for-rare-type-of-bone-cancer" rel="noreferrer noopener">Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer</a>
Additionally,&nbsp;LP-184 received three Rare Pediatric Disease Designations&nbsp;for hepatoblastoma, rhabdomyosarcoma, and malignant rhabdoid tumors, in addition to its existing designation for ATRT, an ultra-rare pediatric brain tumor with the genetic hallmark of loss-of-function or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44523410/lantern-pharma-provides-business-updates-and-fourth-quarter-year-end-2024-financial-results" rel="noreferrer noopener">deletion of the SMARCB1 gene</a>.
Lantern is conducting a Phase 1a trial that is on cohort 11, and early indications of clinical activity have been observed at higher dose levels, consistent <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44523410/lantern-pharma-provides-business-updates-and-fourth-quarter-year-end-2024-financial-results" rel="noreferrer noopener">with preliminary PK data</a>.
<ul>
<li>Dose levels 7, 8, and 9 were cleared without safety concerns during Q4 of 2024, and preliminary PK data suggest dose proportionality with exposure.</li>
<li>Enrollment at dose levels 9 and above is focused on including advanced solid tumor patients who have identified DNA damage repair mutations.</li>
<li>A broader clinical data update is slated for Q2 2025, when recruitment for the trial is expected to be finished, and complete safety and dose-response data are expected to be available.</li>
</ul>
The global TNBC market is estimated at $3-$5 billion annually, with over 300,000 new cases diagnosed worldwide yearly. While homologous recombination-deficient TNBCs are often initially treated with PARP inhibitors, resistance inevitably develops, underscoring the critical need for novel therapeutic approaches.
Price Action: LTRN stock closed at $3.54 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45179856/alnylam-delivers-q1-surprise-analysts-highlight-amvuttra-momentum-and-limited-tariff-risk" target="_blank" rel="noreferrer noopener">Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk</a></li>
</ul>

Biotech

Health Care

Market-Moving Exclusives

Exclusives

General

LTRN

EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial

Rand Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAND#NASDAQ">RAND</a>) reported quarterly earnings of $0.40 per share. This is a 8.11 percent increase over earnings of $0.37 per share from the same period last year. The company reported $2.01 million in sales this quarter. This is a 2.85 percent decrease over sales of $2.07 million the same period last year.

Earnings

RAND

Rand Capital Q1 Adj. EPS $0.40 Up From $0.37 YoY, Sales $2.01M Down From $2.07M YoY

Wells Fargo analyst Roger Read maintains Shell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) with a Overweight and lowers the price target from $83 to $80.

SHEL

Wells Fargo Maintains Overweight on Shell, Lowers Price Target to $80

Wells Fargo analyst Roger Read maintains Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) with a Overweight and lowers the price target from $173 to $164.

Wells Fargo Maintains Overweight on Chevron, Lowers Price Target to $164

EXCLUSIVE: Lantern Pharma Tells Benzinga ''The phase 1b/2 clinical trial plans to evaluate LP-184 in recurrent TNBC patients as both monotherapy and in combination with olaparib'

EXCLUSIVE: Lantern Pharma Tells Benzinga Co. Advances Drug Candidate LP-184 With IND Clearance For Phase 1b/2 Trial In Triple Negative Breast Cancer

Wells Fargo analyst Chris Carey maintains Monster Beverage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) with a Overweight and raises the price target from $65 to $67.

MNST

Wells Fargo Maintains Overweight on Monster Beverage, Raises Price Target to $67

Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has seen a significant drop in&nbsp;new car sales in Spain, while competitors&#8217; electric vehicle sales have seen a sharp increase.
What Happened: Data&nbsp;released by industry group ANFAC&nbsp;on Monday reveals that Tesla sold 571 units in Spain in April, marking a 36% decrease from the same period in the previous year. In contrast, other brands&#8217; electric car sales have surged 54%, indicating a shift in consumer preference, as reported by Reuters.
The decline in Tesla&#8217;s sales is in stark contrast to the overall growth in the electric vehicle market in Spain, suggesting a significant shift in consumer preference towards other brands.
According to ANFAC&#8217;s report, sales of Chinese automakers BYD (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>), MG, and Omoda in Spain have surged by 644%, 80%, and 346%, respectively, so far this year.
This decline in sales is not an isolated incident. Tesla has been losing ground in Europe as well, with a&nbsp;<a href="https://www.benzinga.com/25/04/44975755/tesla-sales-decline-28-in-europe-as-ev-car-market-experiences-growth-report">28% sales decline</a>&nbsp;reported in April 2025. The company&#8217;s market share in the region has dropped to 2% from 2.9% around the same time in the previous year.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/05/45188594/trump-says-i-dont-know-when-asked-if-he-has-to-uphold-the-constitution-when-it-comes-to-mass-deportations" target="_blank" rel="noreferrer noopener">Trump Says &#8216;I Don&#8217;t Know&#8217; When Asked If He Has To Uphold The Constitution When It Comes To Mass Deportations</a>
Why It Matters: Tesla&#8217;s decline highlights broader brand issues, growing competition from Chinese automakers, aging vehicle models, and CEO Elon Musk&#8216;s increasingly polarizing public image. Musk&#8217;s support for far-right politics in Europe has sparked protests and led to vandalism at Tesla showrooms and charging stations in both the U.S. and Europe
In an attempt to expand its global presence, Tesla has started sales <a href="https://www.benzinga.com/25/04/44728787/tesla-to-make-saudi-arabia-debut-amid-infrastructure-challenges">operations in Saudi Arabia</a>. However, the declining sales in Europe and now Spain raise concerns about the company&#8217;s growth prospects in new markets. 
The shift in consumer preference towards other brands in the electric vehicle market is a significant development that could have far-reaching implications for Tesla&#8217;s market dominance. As the company continues to face stiff competition from other brands, it remains to be seen how it will navigate these challenges and maintain its position in the market.
Tesla holds a momentum rating of 92.03% and a quality rating of 95.35%, according to&nbsp;<a href="https://www.benzinga.com/quote/TSLA" target="_blank" rel="noreferrer noopener">Benzinga's Proprietary Edge Rankings</a>. For an in-depth report on more stocks and insights into growth opportunities,&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">sign</a>&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">up for Benzinga Edge.</a>
The shares of Tesla gained over 23% during the past month, whereas on a year-to-date basis, it plunged 24.2%. 
READ MORE:
<ul>
<li><a href="https://benzinga.com/markets/cryptocurrency/25/05/45187736/elizabeth-warren-slams-shady-deal-involving-trump-family-backed-usd1-as-democrats-withdraw-support-for-senarte-crypto-bill" target="_blank" rel="noreferrer noopener">Elizabeth Warren Slams &#8216;Shady&#8217; Deal Involving Trump Family-Backed USD1 As Democrats Withdraw Support For Senarte Crypto Bill &#8211; Benzinga</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Tech

BYDDF

TSLA

Tesla's European Woes Deepen As New Car Sales For April Plunge In Spain While Chinese Rivals Soar

New way of working helps unlock final investment decision (FID) for project offshore Trinidad and Tobago
SLB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) today announced the award of a substantial engineering, procurement, construction and installation (EPCI) contract by bp to its OneSubsea&trade; joint venture and Subsea7 for the Ginger project offshore Trinidad and Tobago.
The Ginger project is the first project award under the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.slb.com%2Fnews-and-insights%2Fnewsroom%2Fpress-release%2F2023%2Fbp-and-subsea-integration-alliance-team-up--to-strengthen-subsea-project-performance&amp;esheet=54248326&amp;newsitemid=20250505099794&amp;lan=en-US&amp;anchor=global+framework+agreement&amp;index=1&amp;md5=63ef53e648c27f20159587c2fedc03a9">global framework agreement</a> between bp and Subsea Integration Alliance partners SLB OneSubsea and Subsea7.
Building on a long-standing successful relationship, this agreement establishes a new way of working that enables system-level optimization through increased transparency and early engagement. Further, the framework defines a novel commercial model that effectively aligns incentives for accelerated and maximized value creation among all stakeholders involved, throughout the life of joint projects.

Contracts

SLB OneSubsea And Subsea7 Awarded EPCI Contract For bp's Ginger Project Offshore Trinidad And Tobago

Chardan Capital analyst Keay Nakae maintains iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) with a Buy and maintains $5 price target.

IBIO

Chardan Capital Maintains Buy on iBio, Maintains $5 Price Target

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Invitation Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVH#NYSE">INVH</a>) with a Market Perform and raises the price target from $36 to $37.

INVH

Keefe, Bruyette & Woods Maintains Market Perform on Invitation Homes, Raises Price Target to $37

Offerings

Nexalin Technology Prices $5M Offering Of 3.85M Shares Of Common Stock At $1.30 Per Share

Keefe, Bruyette &amp; Woods analyst Vasundhara Govil maintains Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) with a Outperform and lowers the price target from $80 to $70.

Keefe, Bruyette & Woods Maintains Outperform on Block, Lowers Price Target to $70

Johnson &amp; Johnson (NYSE:&nbsp;JNJ) today announced new data from the TREMFYA&#xAE; (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC). These data are among 24 abstracts highlighting the Company's research being presented at Digestive Disease Week (DDW) 2025.&nbsp;
Data from the QUASAR LTE study&nbsp;demonstrate patients treated with TREMFYA&#xAE; sustained clinical and endoscopic efficacy at Week 92: a, 1&nbsp;
<ul>
<li>72% of patients were in clinical remissionb with 99% of those patients remaining corticosteroid free for 8 or more weeks through Week 92.</li>
<li>43% of patients were in endoscopic remission.c</li>
<li>Among patients achieving endoscopic improvementd at Week 44, 84% maintained endoscopic improvement through Week 92.</li>
</ul>
Patients treated with TREMFYA&#xAE; sustained clinical and endoscopic remission regardless of prior biologic and/or JAK inhibitor treatment history.

Johnson & Johnson Says Data From QUASAR LTE Study Demonstrate Patients Treated With TREMFYA Sustained Clinical And Endoscopic Efficacy At Week 92

Press Releases

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Apogee Therapeutics

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Beam Therapeutics

Biohaven

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

ImmunityBio

IDEAYA Biosciences

Disc Medicine

Janux Therapeutics

Kymera Therapeutics

Mesoblast Limited - American Depositary Shares

Mesoblast

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Jefferies

Wedbush

Citigroup

JP Morgan

Evercore ISI Group

지난주 가장 좋은 성과를 거든 중형주는 다음과 같다.
<ol>
<li>포니AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>)는 회사가 수익성에 가까워지고 있으며 <a href="https://www.benzinga.com//node/45049945" target="_blank" rel="noreferrer noopener">자율주행 시스템을 더 저렴하게 구축할 수 있다고 발표한 후</a> 주가가 48.36% 상승했다.</li>
<li>힘스 앤 헐스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) 주가는 회사가 노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)와 협력하여 <a href="https://www.benzinga.com//node/45074872" target="_blank" rel="noreferrer noopener">위고비의 모든 용량 패키지를 플랫폼에서 제공하기로 발표</a>한 후 45.32% 급등했다. 뱅크오브아메리카 증권의 애널리스트는 <a href="https://www.benzinga.com/quote/hims/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 22달러에서 26달러로 상향 조정</a>했다.</li>
<li>오디티 테크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) 주가는 회사가 기대 이상의 1분기 재무 결과를 발표하고 FY25 가이던스를 상향 조정하며 <a href="https://www.benzinga.com//node/45111584" target="_blank" rel="noreferrer noopener">2분기 가이던스를 예상치를 초과하여 발표</a>한 후 42.96% 급등했다. 애널리스트들은 <a href="https://www.benzinga.com/quote/ODD/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 상향 조정</a>했다.</li>
<li>멧세라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) 주가는 지난 주 38.42% 상승했다.</li>
<li>CG 온콜로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) 주가는 회사가 크레토스티모진 그레나데노렙벡(cretostimogene grenadenorepvec) 단일요법 데이터를 미국 <a href="https://www.benzinga.com//node/45043205" target="_blank" rel="noreferrer noopener">비뇨기과학회 연례 회의에서 발표했다고 공개</a>한 후 29.86% 상승했다. 일부 애널리스트들은 커버리지를 개시하거나<a href="https://www.benzinga.com/quote/cgon/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 상향 조정</a>했다.</li>
<li>키닉사 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) 주가는 FY25 매출 가이던스를 <a href="https://www.benzinga.com//node/45063476" target="_blank" rel="noreferrer noopener">상향 조정</a>한 후 29.42% 상승했다.</li>
<li>킹소프트 클라우드 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) 주가는 27.34% 상승했다.</li>
<li>프론트도어(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDR#NASDAQ">FTDR</a>) 주가는 회사가 기대 이상의 1분기 재무 결과를 발표하고 FY25 <a href="https://www.benzinga.com//node/45130988" target="_blank" rel="noreferrer noopener">매출 전망을 상향 조정</a>한 후 25.44% 상승했다.</li>
<li>ATI(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) 주가는 기대 이상의 분기 재무 결과를 보고하고 FY25 <a href="https://www.benzinga.com//node/45130989" target="_blank" rel="noreferrer noopener">조정 EPS 가이던스를 상향 조정한 후</a> 25.39% 상승했다.</li>
<li>퍼도세오 에듀케이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRDO#NASDAQ">PRDO</a>) 주가는 <a href="https://www.benzinga.com//node/45149554" target="_blank" rel="noreferrer noopener">1분기 결과를 발표</a>한 후 23.72% 상승했다.</li>
<li>아이리듬 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) 주가는 기대 이상의 1분기 결과를 발표하고 <a href="https://www.benzinga.com//node/45149802" target="_blank" rel="noreferrer noopener">FY25 매출 가이던스를 상향 조정</a>한 후 23.71% 급등했다.</li>
</ol>
사진 출처: Tada Images via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Kiniksa Pharmaceuticals

뉴스

에 대한 최신 뉴스 Kiniksa Pharmaceuticals (NASDAQ:KNSA) 주식

일요일, 5월 04, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌